All In Biotech

Drug Trial Radar · NCT05076006

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

A Pilot Study to Assess Safety and Biomarker Responses of the Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

May 19, 2021

Primary completion

Sep 30, 2023

Study completion Sep 30, 2023

Sponsor

Lead sponsor
Emma GuttmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Oct 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The study team's research involves administrating patients a new investigational drug (a combined TYK/JAK inhibitor) which has been shown to be safe and well tolerated in clinical studies to date, and is being investigated in other conditions, such as AA. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

Conditions

  • Cicatricial Alopecia

Interventions

  • PF-06700841Drug

    Active study drug

  • PlaceboDrug

    placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse EventsTime frame: Week 48
  2. Changes From Baseline in CCL5 Gene Expression Level in Response to PF-06700841Time frame: Baseline, Week 24 and Week 48
  3. Changes From Baseline in CXCR3(TGFB1) Gene Expression Level in Response to PF-06700841Time frame: Baseline, Week 24 and Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.